Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Boston Blades' new team to raise money, awareness for Alzheimer's research

The Alzheimer's Association, Massachusetts/New Hampshire Chapter and the exciting new women's hockey team, the Boston Blades, announced they are teaming up to raise money and awareness for Alzheimer's research.

4 Mar 2011

Researchers transform human embryonic stem cell into neuron that dies early in Alzheimer's disease

Northwestern Medicine researchers for the first time have transformed a human embryonic stem cell into a critical type of neuron that dies early in Alzheimer's disease and is a major cause of memory loss.

4 Mar 2011

New study finds liver instead of the brain as source of Alzheimer’s plaques

Unexpected results from a Scripps Research Institute and ModGene, LLC study could completely alter scientists' ideas about Alzheimer's disease—pointing to the liver instead of the brain as the source of the "amyloid" that deposits as brain plaques associated with this devastating condition. The findings could offer a relatively simple approach for Alzheimer's prevention and treatment.

4 Mar 2011

Lactate plays critical role in formation of long-term memory

Researchers from Mount Sinai School of Medicine have found that lactate, a type of energy fuel in the brain, plays a critical role in the formation of long-term memory. These findings have important implications for common illnesses like Alzheimer's disease, other neurodegenerative disorders, aging-related memory impairment and diabetes. The research is published in the March 4th issue of the journal Cell.

4 Mar 2011

Efficiency of brain function depends on family's genetic makeup

How well our brain functions is largely based on our family's genetic makeup, according to a University of Melbourne led study.

4 Mar 2011

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

The American Academy of Neurology has awarded the 2011 Potamkin Prize to Dennis Dickson, M.D., a neuropathologist at Mayo Clinic in Florida and the Robert E. Jacoby Professor for Alzheimer's Disease Research.

3 Mar 2011

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.

3 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

3 Mar 2011

Ibuprofen may protect against development of Parkinson's disease

New research suggests that ibuprofen may offer protection against developing Parkinson's disease, according to one of the largest studies to date investigating the possible benefits of the over-the-counter drug on the disease. The study is published in the March 2, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Mar 2011

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

2 Mar 2011

Study: Light-to-moderate alcohol consumption may decrease risk of dementia

Experts agree that long-term alcohol abuse is detrimental to memory function and can cause neuro-degenerative disease. However, according to a study published in Age and Ageing by Oxford University Press today, there is evidence that light-to-moderate alcohol consumption may decrease the risk of cognitive decline or dementia.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

New study: Alzheimer's disease can be inherited from your mother than father

Results from a new study contribute to growing evidence that if one of your parents has Alzheimer's disease, the chances of inheriting it from your mother are higher than from your father.

1 Mar 2011

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals for the development of an active vaccination programme against Alzheimer's disease.

1 Mar 2011

New nasal vaccine holds promise against both Alzheimer's disease and stroke

One in eight Americans will fall prey to Alzheimer's disease at some point in their life, current statistics say. Because Alzheimer's is associated with vascular damage in the brain, many of them will succumb through a painful and potentially fatal stroke.

1 Mar 2011

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.

28 Feb 2011

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis Technologies Inc. is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

28 Feb 2011

Alzheimer's Disease News and Research

Further Reading

Boston Blades' new team to raise money, awareness for Alzheimer's research

Researchers transform human embryonic stem cell into neuron that dies early in Alzheimer's disease

New study finds liver instead of the brain as source of Alzheimer’s plaques

Lactate plays critical role in formation of long-term memory

Efficiency of brain function depends on family's genetic makeup

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Ibuprofen may protect against development of Parkinson's disease

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Study: Light-to-moderate alcohol consumption may decrease risk of dementia

Mathematical model predicts lifespan of stem cells

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

New study: Alzheimer's disease can be inherited from your mother than father

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

New nasal vaccine holds promise against both Alzheimer's disease and stroke

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News